Allergan, Adamas: New Dosage Strengths For NAMZARIC Available In US

(RTTNews) - Allergan plc (AGN), a pharmaceutical company, and Adamas Pharmaceuticals, Inc. (ADMS) announced Thursday the U.S. availability of new dosage strengths for NAMZARIC (Memantine and Donepezil Hydrochlorides) extended release for the treatment of moderate to severe Alzheimer's Disease.

The companies said that all four dosage strengths of NAMZARIC extended-release capsules that allow patients on donepezil 10 mg to start directly on NAMZARIC are now available by prescription in pharmacies throughout the U.S.

NAMZARIC is a once-daily, fixed-dose combination of memantine hydrochloride (a NMDA receptor antagonist) and donepezil hydrochloride (an acetylcholinesterase inhibitor, AChEI) for the treatment of moderate to severe Alzheimer's Disease in patients stabilized on 10 mg of donepezil hydrochloride once daily.

NAMZARIC'S new indication and dosage strengths were approved by the U.S. Food and Drug Administration in July 2016.

The companies noted that approximately 75% of patients diagnosed with Alzheimer's Disease are in the moderate to severe stage of the disease and yet only about one-third of these patients are treated with combination therapy.

NAMZARIC will be commercially available in 30 count bottles in 7 mg/10 mg, 14 mg/10 mg, 21 mg/10 mg and 28 mg/10 mg. NAMZARIC is covered broadly by Medicare Part D prescription plans.

In pre-market activity, Allergan shares were gaining 0.20 percent at $238.88.